<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20140817018834N8</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-06-10</date_registration>
      <primary_sponsor>Vice Chancellor for research of Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of antibiotic prophylaxis in implant surgery with guided bone regeneration.</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of antibiotic prophylaxis on  clinical and patient reported outcome  and  inflammation-related indicators of oral implant therapy with guided bone regeneration.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-06-13</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56364</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The randomization method will be block.
Patients will be randomly allocated in to the intervention and control groups by block randomization technique. A number of two blocks (A and B) will be considered. With the help of random numbers, a  random number will be assigned to each group and this will determine the type of intervention. For blindness with the help of random number and code for each patient, a person other than the patient surgeon puts the type of intervention in the envelope. The type of intervention  (use of prophylaxis or not ) is recommended to the patient , Blinding description: Due to the design of the study, it is not possible to blind the participants,  principal investigator and clinic staff, and Each person's data are made available to the data analyzer and the Outcome assessor without knowing the case group or being in control.</study_design>
      <phase>3</phase>
      <hc_freetext>Horizontal alveolar bone defects..</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In patients who are candidates for implant placement,  the guided bone regeneration treatment will be performed using one type of membrane and one type of bone graft. In this group 2 gr amoxicillin will be prescribed one hour before treatment. After surgery, amoxicillin 500 mg (Abidi) every 8 hours for 7 days and ibuprofen 400 mg every 6 hours for 5 days will be prescribed. Intervention 2: Control group:  In patients who are candidates for implant placement, the guided bone regeneration treatment will be performed using one type of membrane and one type of bone graft. In this group, no prophylactic antibiotic will be prescribed before treatment. after surgery, amoxicillin 500 mg (Abidi) every 8 hours for 7 days and ibuprofen 400 mg every 6 hours for 5 days will be prescribed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data is related to the main consequence after unidentifiable people are shared.

When:
6 month after printing the results.

To whom:
Researchers working in academic and scientific institutions.

Conditions:
If you are to submit a article to a journal, they will be asked to receive the data.

Where to obtain:
Person responsible for scientific study.
nasran@mums.ac.ir

How to obtain:
Sending an email to the given address and waiting time to receive a response less than a month.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nahid Nasrabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mashhad faculty of dentistry, Vakil Abad Blv, Mashhad, Razavi khorasan province</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177948959</zip>
        <telephone>+98 51 3882 9501</telephone>
        <email>nasran@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nahid Nasrabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mashhad faculty of dentistry, Vakil Abad Blv , Mashhad, Razavi khorasan province</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177948959</zip>
        <telephone>+98 51 3882 9501</telephone>
        <email>nasran@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>•	An age range of 20 to 50 years
•	The extent of the lesion (horizontal bone augmentation) is about one or two teeth
•	No previous surgical procedures have been initiated in the specific area
•	The patient's informed consent
•Absence of systemic diseases that interfere healing process, such as diabetes
•	Non smoker
•Do not take drugs interfere with the treatment process, such as corticosteroids
•	Dehiscence defects in buccal surface of the implant</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>•	Do not refer for routine follow up visits
•	Patients who are allergic to amoxicillin
•	The presence of severe infection in the oral cavity
•	Wound opening during bone transplantation surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>k08.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Atrophy of edentulous alveolar ridge</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In patients who are candidates for implant placement,  the guided bone regeneration treatment will be performed using one type of membrane and one type of bone graft. In this group 2 gr amoxicillin will be prescribed one hour before treatment. After surgery, amoxicillin 500 mg (Abidi) every 8 hours for 7 days and ibuprofen 400 mg every 6 hours for 5 days will be prescribed.</i_keyword>
      <i_keyword>Control group:  In patients who are candidates for implant placement, the guided bone regeneration treatment will be performed using one type of membrane and one type of bone graft. In this group, no prophylactic antibiotic will be prescribed before treatment. after surgery, amoxicillin 500 mg (Abidi) every 8 hours for 7 days and ibuprofen 400 mg every 6 hours for 5 days will be prescribed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: 1-3-7 days after surgery. Method of measurement: The patient is asked about the amount of pain by telephone using the visual analogue scale index on the first, third, and seventh days, and the patient is asked to rate their pain experience on a scale from 0 to 10 .</prim_outcome>
      <prim_outcome>Swelling. Timepoint: 1_3_7 days after surgery. Method of measurement: On the first, third and seventh day, the patient is asked about the presence or absence of swelling. due to special conditions in COVID-19 prevalence and attracting patient involvement and cooperation, On the third day, the patient will be examined remotely by sending a full face photo.</prim_outcome>
      <prim_outcome>Bleeding. Timepoint: 1_3_7 days after surgery. Method of measurement: On the first, third and seventh day, the patient is asked about the presence or absence of bleeding. due to special conditions in COVID-19 prevalence and attracting patient involvement and cooperation, On the third day, the patient will be examined remotely by sending a full face photo.</prim_outcome>
      <prim_outcome>Hematoma. Timepoint: 1_3_7 days after surgery. Method of measurement: On the first, third and seventh day, the patient is asked about the presence or absence of hematoma. due to special conditions in COVID-19 prevalence and attracting patient involvement and cooperation, On the third day, the patient will be examined remotely by sending a full face photo.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Implant survival. Timepoint: 3 months after surgery. Method of measurement: Clinical and radiography examination.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice Chancellor for research of Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-05-12</approval_date>
        <contact_name>Ethics committee of Mashhad University of Medical Sciences_Mashhad faculty of dentistry</contact_name>
        <contact_address>Mashhad faculty of dentistry, Vakil Abad Blv, Mashhad Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
